47
471A.F aTyr Pharma Inc
- Market cap
- EUR 17.4K
- P/E
- -
- P/B
- 0.02x
- ROE
- -154.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 471A.F undervalued?
Graham numberThe Graham number of aTyr Pharma Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
aTyr Pharma Inc fundamental analysis
No fundamental analysis for aTyr Pharma Inc yet.
aTyr Pharma Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About aTyr Pharma Inc
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (…
Full company profileaTyr Pharma Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
aTyr Pharma Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | 0.00 | 0.00 | 422K | 10.5M | 2.05M | 10.4M | 353K | 235K | 190K | 0.00 |
| Operating Income | -57.9M | -47.1M | -32.8M | -23.0M | -15.9M | -34.0M | -46.4M | -54.9M | -67.9M | -77.6M | -54.8M |
| EBITDA | - | -46.4M | -32.1M | -21.6M | -14.6M | - | -44.7M | -52.2M | -66.4M | -76.1M | -53.2M |
| Net Income | -57.9M | -48.2M | -34.5M | -23.6M | -16.2M | -33.8M | -45.3M | -50.4M | -64.0M | -74.1M | -52.5M |
| EPS | - | -23 | -16 | -6.06 | -1.47 | -1.21 | -1.54 | -32 | -30 | -30 | -21 |
| Balance Sheet | |||||||||||
| Total Assets | 80.5M | 89.4M | 52.7M | 36.2M | 38.7M | 116M | 95.8M | 121M | 96.8M | 93.0M | 59.8M |
| Total Liabilities | 17.7M | 25.1M | 19.1M | 15.2M | 7.24M | 6.41M | 24.5M | 30.2M | 27.0M | 25.7M | 26.0M |
| Shareholders' Equity | 62.8M | 64.2M | 33.7M | 21.2M | 31.7M | 109M | 71.3M | 90.7M | 70.0M | 67.5M | 34.0M |
| Cash & Short-term Investments | 38.4M | 21.1M | 23.0M | 9.21M | 17.0M | 2.34M | 9.98M | 22.5M | 11.1M | 10.7M | 13.1M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -52.9M | -42.4M | -31.1M | -20.0M | -15.3M | -33.1M | -41.9M | -33.2M | -69.1M | -62.0M | -41.8M |
| Capital Expenditure | 600K | 1.31M | 594K | 79.0K | 202K | 192K | 1.64M | 4.22M | 65.0K | 77.0K | 341K |
| Free Cash Flow | - | -43.7M | -31.7M | -20.1M | -15.5M | -33.3M | -43.5M | -37.4M | -69.2M | -62.1M | -42.2M |
| Ratios | |||||||||||
| ROE | -92.1% | -75.0% | -102.6% | -111.4% | -51.3% | -30.9% | -63.6% | -55.6% | -91.4% | -109.8% | -154.4% |
| ROA | -71.8% | -53.9% | -65.4% | -65.2% | -41.9% | -29.2% | -47.3% | -41.8% | -66.1% | -79.7% | -87.8% |
| Net Profit Margin | - | - | - | -5,593.1% | -155.2% | -1,644.8% | -436.5% | -14,274.5% | -27,243.8% | -39,009.5% | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
aTyr Pharma Inc dividends
aTyr Pharma Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:40 on Oct 29, 2026.
Who owns aTyr Pharma Inc
- Insiders 0.31%
- Institutions 36.18%
- Public & others 63.51%
- Shares outstanding 3.00M
- Free float 2.44M
aTyr Pharma Inc company profile
- Company name
- aTyr Pharma Inc
- Ticker
- 471A.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 58
- Fiscal year end
- December
- Address
- 10240 Sorrento Valley Road, San Diego, CA, United States, 92121
- Phone
- 858 731 8389
- Website
- atyrpharma.com
About aTyr Pharma Inc
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD. The company develops ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment of fibrosis; ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders; and develops and tests ATYR2810, the Company's monoclonal antibody that targets the neuropilin-2 (NRP2) receptor for the treatment of aggressive cancers. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
aTyr Pharma Inc management
1- Dr. Sanjay S. Shukla M.D., M.S.President, CEO & Director · born 1972